Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab subcutaneous maintenance therapy in Crohn's disease after intravenous induction
2015-000481-58Phase 3Completed
- Sponsor
- Takeda
- Start
- Jan 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing Vedolizumab SC maintenance with Placebo maintenance (2 arms). Primary endpoint: Clinical remission at Week 52. Started Jan 2016; status: completed.
02
Drugs
vedolizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2015-000481-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000481-58.